News

A rock-painting contest in Las Vegas. A fashion show in New York. A 7,000-meter race around the Washington Monument that’ll coincide with a similar #Racefor7 event in Bengaluru and Mumbai, India. From Athens to Atlanta, from San Diego to Sydney, people across the globe will mark World Rare Disease…

PTC Therapeutics is recruiting Duchenne muscular dystrophy (DMD) patients ages 5 and older and with a nonsense mutation for a long-term Phase 3 study to characterize the effects of Translarna (ataluren) on disease progression. The trial (NCT03179631) opened in July 2017 and enrolling patients at eight sites across…

Measuring the physical strength of individual cells is now 100 times faster with a new device called FLECS developed by researchers at UCLA and Rutgers University. FLECS allows researchers to measure the strength of thousands of individual cells at a time and could make it easier for them…

PTC Therapeutics announced the start of its fourth annual STRIVE awards program for Duchenne muscular dystrophy (DMD). STRIVE — which stands for Strategies to Realize Innovation, Vision and Empowerment — supports programs run by nonprofit patient advocacy groups that aim to increase disease diagnosis, awareness and education, and train…

Treatment with edasalonexent (CAT-1004) showed sustained preservation of muscle function in a Phase 1/2 trial in boys with Duchenne muscular dystrophy (DMD), according to Catabasis Pharmaceuticals. The MoveDMD trial (NCT02439216) is investigating the safety and efficacy of edasalonexent in boys ages 4-7 at enrollment with any DMD-related mutation.

A new approach to CRISPR-Cas9 gene-editing technology, called myoediting, successfully restored dystrophin production and contraction force in heart muscle cells of Duchenne muscular dystrophy (DMD) patients. The new strategy, developed by U.S. and German researchers, targets sites located in “hot spots” of mutations along the dystrophin gene, allowing its…

The U.K.-based Duchenne Research Fund has granted £320,000 ($441,760) to researchers at Imperial College London to develop a bodysuit that may improve treatment decisions in Duchenne muscular dystrophy (DMD). The fund aims to help foster the development of new treatments for DMD by establishing collaborations between scientists, charities, and…

Santhera Pharmaceuticals recently launched an expanded access program (EAP) to allow certain Duchenne muscular dystrophy (DMD) patients in the U.S. to gain access Raxone (idebenone). Raxone is not approved to treat Duchenne MD by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The BreatheDMD…

CAP-1002, a cell therapy being developed by Capricor Therapeutics to treat Duchenne muscular dystrophy (DMD), has won a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). RMAT status is given to regenerative medicine therapies that show potential to treat serious conditions lacking available therapies.

European and Japanese researchers used an artificial chromosome to generate the dystrophin protein that’s missing in Duchenne muscular dystrophy. The chromosome delivered a two-gene package capable of producing the missing protein to a mouse model of the disease. The team also used it in a lab setting involving human cells.